During the corresponding time, Ardelyx Inc recorded a revenue increase by 23.77 % year on year, sequentially revenue grew by 27.95 %. While revenue at the Ardelyx Inc 's corporate clients
Ardelyx Inc's Comment on Sales, Marketing and Customers
The text addresses regulatory laws that impact activities related to product promotion, pricing, reimbursement, and reporting requirements involving healthcare providers, including physicians, non-physician practitioners, and teaching hospitals.
WALTHAM, Mass. March 31, 2025 Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative first-in-class medicines, has exciting news to share with the medical community. An abstract highlighting a post-hoc analysis of the OPTIMIZE Study, which represents a substantial advancement in the understanding of XPHOZAH (tenapanor), has been accepted for poster presentation at the esteemed National Kidney Foundation (NKF) Spring Clinical Meetings scheduled from April 10-13, 2025, in Boston. Background on Ardelyx and XPHOZAHArdelyx was established with a commitment to addressing significant unmet medical needs through the creatio...
In a timely announcement, the Rosen Law Firm, recognized as a leading global counsel specializing in investor rights, has urged investors of Ardelyx, Inc. (NASDAQ: ARDX) to take swift and decisive action ahead of the imminent October 15, 2024, deadline for lead plaintiffs in a significant securities class action. This alert is primarily directed towards individuals who acquired Ardelyx securities during the class period spanning from October 31, 2023, to July 1, 2024.The importance of this deadline cannot be overstated, as it marks a critical juncture for investors seeking to secure their rights and potentially recover losses incurred during this tumultuous trading period. The securities class action is root...
In the dynamic landscape of financial markets, investor confidence is often swayed by the performance metrics of companies and their legal standings. Ardelyx, Inc. (NASDAQ: ARDX), a biopharmaceutical company, currently epitomizes this intersection of vulnerability and potential as it contends with both a significant financial loss and a class-action lawsuit. Investor Rights and Legal ContextRecent communication from Rosen Law Firm a recognized promoter of investor rights highlights the ongoing challenges faced by Ardelyx shareholders. Investors who purchased Ardelyx securities during the class period from October 31, 2023, to July 1, 2024, are urged to act promptly as they confront the upcoming lead plaintif...
In an exciting development for patients with chronic kidney disease (CKD) undergoing dialysis, Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company, has announced the publication of two plain language summaries detailing clinical trial findings for its innovative drug, XPHOZAH (tenapanor). These summaries, featured in the esteemed journal Current Medical Research and Opinion , are specifically designed to enhance the comprehension of safety and efficacy data for patients, their families, and caregivers.Launched on July 31, 2024, the summaries cover results from two pivotal clinical trials: NORMALIZE and OPTIMIZE. Understanding the complexities of clinical data can often be challenging for pa...
In recent years, hyperphosphatemia, a condition characterized by abnormally high levels of phosphate in the blood, has become an increasingly prevalent and challenging issue within the healthcare industry. High phosphate levels contribute to various complications, especially among patients with kidney diseases. As a result, biopharmaceutical company Ardelyx, Inc., with a commitment to addressing significant unmet medical needs, has developed a groundbreaking drug called XPHOZAH (tenapanor). This article explores the latest data presented at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings regarding the positive clinical observations of XPHOZAH.Understanding Hyperphosphatemia and Its Consequ...
Ardelyx, Inc. Empowers New Talent with Substantial Employment Inducement Grants WALTHAM, Mass., May 14, 2024 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical firm dedicated to the discovery, development, and commercialization of pioneering, first-in-class medicines addressing significant unmet medical needs, recently announced an impactful initiative aimed at bolstering their workforce. On May 6, 2024, the compensation committee of Ardelyx s board of directors conferred a series of inducement grants to a total of 58 new non-executive employees, marking an important milestone in the company’s growth trajectory.The inducements consisted of stock options to purchase an aggregate of 511,500 shares of Arde...
Ardelyx Inc’s Comment on Sales, Marketing and Customers
The text addresses regulatory laws that impact activities related to product promotion, pricing, reimbursement, and reporting requirements involving healthcare providers, including physicians, non-physician practitioners, and teaching hospitals.
Sources:
Ardelyx inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ardelyx inc’s corporate clients.
For your research, we’ve provided 9 tables on Ardelyx inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
174.97 %